Collplant Historical Financial Ratios
| CLGN Stock | USD 4.25 0.00 0.00% |
Collplant Biotechnologies is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 4.81 or Days Sales Outstanding of 12.43 will help investors to properly organize and evaluate Collplant Biotechnologies financial condition quickly.
Collplant |
About Collplant Financial Ratios Analysis
Collplant BiotechnologiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Collplant Biotechnologies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Collplant financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Collplant Biotechnologies history.
Collplant Biotechnologies Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Collplant Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Collplant Biotechnologies sales, a figure that is much harder to manipulate than other Collplant Biotechnologies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Price To Book Ratio
A ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share.Most ratios from Collplant Biotechnologies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Collplant Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.At this time, Collplant Biotechnologies' Cash Per Share is very stable compared to the past year. As of the 28th of November 2024, Net Debt To EBITDA is likely to grow to 3.85, while Price To Sales Ratio is likely to drop 6.31.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 6.3 | 10.99 | 13.09 | 12.43 | PTB Ratio | 3.61 | 2.85 | 2.57 | 4.81 |
Collplant Biotechnologies fundamentals Correlations
Click cells to compare fundamentals
Collplant Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Collplant Biotechnologies fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 12.26 | 12.09 | 10.43 | 308.12 | 6.64 | 6.31 | |
| Ptb Ratio | 6.95 | 16.57 | 3.61 | 2.85 | 2.57 | 4.81 | |
| Days Sales Outstanding | 12.44 | 49.36 | 6.3 | 10.99 | 13.09 | 12.43 | |
| Book Value Per Share | 0.82 | 0.65 | 4.53 | 2.93 | 2.49 | 2.77 | |
| Free Cash Flow Yield | (0.25) | (0.067) | 0.005592 | (0.16) | (0.0511) | (0.0536) | |
| Operating Cash Flow Per Share | (1.14) | (0.65) | 0.25 | (1.24) | (0.24) | (0.25) | |
| Stock Based Compensation To Revenue | 0.49 | 0.27 | 0.1 | 7.27 | 0.18 | 0.17 | |
| Capex To Depreciation | 2.77 | 0.79 | 2.06 | 1.22 | 0.87 | 0.92 | |
| Pb Ratio | 6.95 | 16.57 | 3.61 | 2.85 | 2.57 | 4.81 | |
| Ev To Sales | 12.19 | 12.1 | 9.82 | 218.68 | 4.5 | 4.27 | |
| Free Cash Flow Per Share | (1.44) | (0.72) | 0.0915 | (1.36) | (0.33) | (0.34) | |
| Roic | (2.44) | (1.15) | 0.002458 | (0.52) | (0.27) | (0.28) | |
| Inventory Turnover | 2.12 | 2.38 | 1.85 | 0.28 | 2.79 | 2.93 | |
| Net Income Per Share | (2.95) | (0.84) | 0.041 | (1.52) | (0.62) | (0.65) | |
| Days Of Inventory On Hand | 172.5 | 153.44 | 196.79 | 1.3K | 130.89 | 124.35 | |
| Payables Turnover | 2.26 | 3.76 | 1.94 | 0.35 | 2.03 | 1.02 | |
| Sales General And Administrative To Revenue | 4.95 | 0.69 | 1.56 | 0.75 | 0.87 | 0.82 | |
| Research And Ddevelopement To Revenue | 1.9 | 0.66 | 0.49 | 34.3 | 0.96 | 0.91 | |
| Capex To Revenue | 0.64 | 0.0846 | 0.1 | 4.4 | 0.0871 | 0.0827 | |
| Cash Per Share | 0.76 | 0.48 | 4.34 | 2.69 | 2.34 | 2.44 | |
| Pocfratio | (4.98) | (16.66) | 65.21 | (6.73) | (26.34) | (25.02) | |
| Interest Coverage | (121.13) | (164.68) | 1.76 | (502.85) | (751.2) | (713.64) | |
| Capex To Operating Cash Flow | (0.26) | (0.12) | 0.64 | (0.0961) | (0.35) | (0.33) | |
| Pfcf Ratio | (3.95) | (14.92) | 178.83 | (6.14) | (19.58) | (18.6) | |
| Days Payables Outstanding | 161.81 | 97.03 | 188.23 | 1.0K | 179.66 | 170.68 | |
| Income Quality | 0.51 | 0.77 | 10.55 | 0.81 | 0.39 | 0.37 | |
| Roe | (3.6) | (1.3) | 0.009065 | (0.52) | (0.25) | (0.26) | |
| Ev To Operating Cash Flow | (4.95) | (16.68) | 61.4 | (4.77) | (17.83) | (16.94) | |
| Pe Ratio | (1.93) | (12.77) | 398.76 | (5.5) | (10.37) | (9.85) | |
| Return On Tangible Assets | (1.37) | (0.54) | 0.008023 | (0.45) | (0.21) | (0.22) | |
| Ev To Free Cash Flow | (3.93) | (14.94) | 168.37 | (4.36) | (13.25) | (12.59) | |
| Earnings Yield | (0.52) | (0.0783) | 0.002508 | (0.18) | (0.0964) | (0.1) | |
| Net Debt To E B I T D A | 0.0244 | (0.0111) | (11.38) | 1.67 | 3.67 | 3.85 | |
| Current Ratio | 1.46 | 1.68 | 14.96 | 10.2 | 8.62 | 4.36 | |
| Receivables Turnover | 29.34 | 7.39 | 57.93 | 33.22 | 27.89 | 16.98 | |
| Graham Number | 7.37 | 3.51 | 2.04 | 10.0 | 5.87 | 11.11 |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Collplant Stock
| 0.82 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Collplant Stock
| 0.8 | PHVS | Pharvaris BV | PairCorr |
| 0.69 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.61 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.61 | PLRX | Pliant Therapeutics | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.